Results from a Phase 3, Multicenter, Noninferiority Study of Ravulizumab (ALXN1210) versus Eculizumab (ECU) in Adult Patients (pts) with Paroxysmal Nocturnal Hemoglubinuria (PNH) Naive to Complement Inhibitors (CI)
- Resource Type
- Source
- Science meets clinical practice.
- Subject
medicine.medical_specialty Adult patients business.industry Internal medicine medicine Complement Inhibitors Nocturnal Eculizumab business Gastroenterology medicine.drug - Language
- ISSN
- 2567-5761